Trial Profile
A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma ILLUMINATE-204)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Feb 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Tilsotolimod (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms ILLUMINATE-204
- Sponsors Aceragen; Idera Pharmaceuticals
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 15 Sep 2020 According to an Idera Pharmaceutical media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, to be held September 19-21, 2020.